We are live on ! Find out more
KNTE

Kinnate Biopharma Inc. Common Stock
KNTE

Delisted

KNTE was delisted on the 2nd of April, 2024.

Back to rankings

84 hedge funds and large institutions have $472M invested in Kinnate Biopharma Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 27 increasing their positions, 19 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

220% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 5

42% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 19

15% more funds holding

Funds holding: 73 → 84 (+11)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

4% less capital invested

Capital invested by funds: $493M → $472M (-$20.1M)

Holders
84
Holders Change
+11
Holders Change %
+15.07%
% of All Funds
1.45%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.1%
New
16
Increased
27
Reduced
19
Closed
5
Calls
$569K
Puts
–
Net Calls
+$569K
Net Calls Change
-$46K

Top Buyers

Rank Fund Capital Flow
1
APM
Avidity Partners Management
Texas
+$15.9M
2
WP
Woodline Partners
California
+$3.46M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$3.1M
4
RSCM
Rock Springs Capital Management
Maryland
+$1.68M
5
Millennium Management
Millennium Management
New York
+$1.03M

Top Sellers

Rank Fund Capital Flow
1
VVA
Vida Ventures Advisors
Massachusetts
-$7.06M
2
NI
Nextech Invest
Switzerland
-$4.53M
3
BC
Boxer Capital
California
-$4.25M
4
DCM
DAFNA Capital Management
California
-$1.92M
5
WSL
Western Standard LLC
California
-$1.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
EC
26
EcoR1 Capital
California
$2.09M – – –
Charles Schwab
27
Charles Schwab
California
$1.75M +$42.8K +3,269 +2%
Deutsche Bank
28
Deutsche Bank
Germany
$1.56M -$25.5K -1,951 -1%
AG
29
Artal Group
Luxembourg
$1.49M – – –
Victory Capital Management
30
Victory Capital Management
Texas
$1.38M -$39K -2,980 -3%
N
31
Nuveen
North Carolina
$1.33M -$419 -32 -0%
Renaissance Technologies
32
Renaissance Technologies
New York
$1.2M +$64.1K +4,900 +5%
Bank of New York Mellon
33
Bank of New York Mellon
New York
$1.16M +$115K +8,792 +10%
Millennium Management
34
Millennium Management
New York
$943K +$1.03M +78,889 New
DCM
35
DAFNA Capital Management
California
$933K -$1.92M -146,377 -65%
GCP
36
GSA Capital Partners
United Kingdom
$876K +$221K +16,898 +30%
CS
37
Candriam SCA
Luxembourg
$793K +$868K +66,357 New
RhumbLine Advisers
38
RhumbLine Advisers
Massachusetts
$547K +$36.9K +2,816 +7%
Bank of America
39
Bank of America
North Carolina
$534K -$174K -13,306 -23%
Morgan Stanley
40
Morgan Stanley
New York
$518K -$152K -11,626 -21%
Dimensional Fund Advisors
41
Dimensional Fund Advisors
Texas
$465K +$98.4K +7,515 +24%
TI
42
Trexquant Investment
Connecticut
$288K +$140K +10,697 +80%
State Board of Administration of Florida Retirement System
43
State Board of Administration of Florida Retirement System
Florida
$231K – – –
JP Morgan Chase
44
JP Morgan Chase
New York
$228K +$20.5K +1,567 +9%
New York State Common Retirement Fund
45
New York State Common Retirement Fund
New York
$226K +$1.35K +103 +0.5%
MIM
46
MetLife Investment Management
New Jersey
$186K – – –
Barclays
47
Barclays
United Kingdom
$185K -$2.98K -228 -1%
AIG
48
American International Group
New York
$166K +$2.55K +195 +1%
Mirae Asset Global Investments
49
Mirae Asset Global Investments
South Korea
$147K +$161K +12,302 New
VOYA Investment Management
50
VOYA Investment Management
Georgia
$144K +$13.4K +1,025 +9%
1
2
3 4

KNTE Hedge Fund Activity: Q3 2022 in Review

84 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Kinnate Biopharma Inc. Common Stock (KNTE) for Q3 2022, worth a combined $472M — down 4.1% from $493M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new KNTE positions and 5 closed out — a net gain of 11 holders — while 27 added to existing stakes and 19 trimmed.

The largest buyer was Avidity Partners Management, opening a new position worth an estimated $15.9M. The largest seller was Vida Ventures Advisors, cutting an estimated $7.06M.

  • 84 institutional investors held Kinnate Biopharma Inc. Common Stock (KNTE) as of Q3 2022, up from 73 in Q2 2022.
  • Funds reported $472M of Kinnate Biopharma Inc. Common Stock stock for Q3 2022, down 4.1% quarter-over-quarter.
  • 16 funds opened new Kinnate Biopharma Inc. Common Stock positions in Q3 2022 and 5 closed out, a net change of +11 holders.
  • The largest Kinnate Biopharma Inc. Common Stock buyer in Q3 2022 was Avidity Partners Management, an estimated $15.9M added.
  • The largest Kinnate Biopharma Inc. Common Stock seller in Q3 2022 was Vida Ventures Advisors, an estimated $7.06M sold.

Based on aggregated 13F filings for Q3 2022.